27 reports

Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – US Overview An interview with a US key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline appr

  • Meningococcal
  • Vaccine
  • United States
  • Market Size
  • Social Conditions

Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – UK Overview An interview with a UK key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline appr

  • Meningococcal
  • Vaccine
  • United Kingdom
  • Market Size
  • Social Conditions
  • MENINGOCOCCAL [SEROTYPES A, B, C] VACCINE - DRUG PROFILE
  • MENINGOCOCCAL [SEROTYPES C, Y] VACCINE - DRUG PROFILE

Up to one in ten of those infected with meningococcal disease may die and around one in five may suffer from serious long-term disabilities, including brain damage, deafness, and limb loss.

  • Meningococcal
  • China
  • United States
  • World
  • Product Initiative
  • A cohort study of 868 IMD survivors in Canada between 2002-2011
  • 3.1 BIBLIOGRAPHY

Meningococcal disease.

  • Laboratory
  • Meningococcal
  • Brazil
  • United States
  • Forecast
  • MENINGOCOCCAL [SEROTYPES A, B, C] VACCINE - DRUG PROFILE
  • MENINGOCOCCAL [SEROTYPES C, Y] VACCINE - DRUG PROFILE

About one in ## infants who contract meningococcal disease may die.

  • Meningococcal
  • China
  • United States
  • World
  • Product Initiative
  • MENINGOCOCCAL [SEROTYPES A, C] VACCINE - DRUG PROFILE
  • (HAEMOPHILUS INFLUENZAE [SEROTYPE B] + MENINGOCOCCAL [SEROTYPES A, C]) VACCINE - DRUG PROFILE

Neisseria meningitides are one of these, and causes meningococcal meningitis.

  • Infectious Disease
  • Meningococcal
  • Therapy
  • United States
  • Product Initiative
  • DEBT OFFERING
  • WALVAX BIOTECHNOLOGY TO ACQUIRE SHANDONG BIOLOGICAL MEDICINE COMPANY FOR US$48.5 MILLION

One clinical candidate-NBT## ADC-## selected by Genor Pharma will go for further development for IND application in 2016.

  • Biotechnology
  • Meningococcal
  • Pharmaceutical
  • China
  • Walvax Biotechnology Co., Ltd
  • MENINGOCOCCAL [SEROTYPE B] VACCINE ALONE OR IN COMBINATION HAS THE HIGHEST NUMBER OF NEISSERIA MENINGITIDIS INFECTIONS ONGOING CLINICAL TRIALS.
  • Clinical Trial profile. 5 Trial Title

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Infectious Disease
  • Meningococcal
  • Vaccine
  • World
  • GlaxoSmithKline plc
  • MENINGOCOCCAL [SEROTYPES A, C] VACCINE - DRUG PROFILE
  • Meningitis - Drug Profiles

Neisseria meningitides are one of these, and causes meningococcal meningitis.

  • Meningococcal
  • Pharmaceutical
  • United States
  • Product Initiative
  • ContraFect Corporation
  • Clinical Trial profile. 33 Trial Title
  • Official Title

## ## ## ## United States ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## France ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## Italy Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)T

  • Anti-Infective
  • Meningococcal
  • World
  • Product Initiative
  • Pfizer Inc.

Nimenrix

8770 10000 7800

Nimenrix ## OVERVIEW ## Drug Overview ## Product Profiles ## Nimenrix : Meningococcal vaccines LIST OF TABLES ## Table ##: Nimenrix drug profile ## Table ##: Approval history of Nimenrix for meningococcal vaccination in the five major EU markets ## Table ##: Late-phase trials of Nimen

  • Meningococcal
  • Vaccine
  • Europe
  • European Union
  • Market Description

Trumenba

8770 10000 7800

Trumenba ## OVERVIEW ## Drug Overview ## Product Profiles ## Trumenba : Meningococcal vaccines LIST OF TABLES ## Table ##: Trumenba drug profile ## Table ##: Approval history of Trumenba for meningococcal vaccination in the US and five major EU markets ## Table ##: Late-phase trials o

  • Meningococcal
  • Pathology
  • Vaccine
  • United States

Menveo

8770 10000 7800

Menveo ## OVERVIEW ## Drug Overview ## Product Profiles ## Menveo : Meningococcal vaccines LIST OF TABLES ## Table ##: Menveo drug profile ## Table ##: Approval history of Menveo for meningococcal vaccination in the US and five major EU markets ## Table ##: Late-phase trials of Menveo

  • Meningococcal
  • Vaccine
  • European Union
  • United States
  • Forecast

Menactra

8770 10000 7800

Menactra ## OVERVIEW ## Drug Overview ## Product Profiles ## Menactra : Meningococcal vaccines LIST OF TABLES ## Table ##: Menactra drug profile ## Table ##: Approval history of Menactra for meningococcal vaccination in the US and Japan ## Table ##: Late-phase trials of Menactra for

  • Meningococcal
  • Therapy
  • Vaccine
  • United States
  • Price

Bexsero

8770 10000 7800

Bexsero ## OVERVIEW ## Drug Overview ## Product Profiles ## Bexsero : Meningococcal vaccines LIST OF TABLES ## Table ##: Bexsero drug profile ## Table ##: Approval history of Bexsero for meningococcal vaccination in the US and five major EU markets ## Table ##: Late-phase trials of Be

  • Meningococcal
  • Therapy
  • Vaccine
  • European Union
  • United States

MenABCW-135Y

8770 10000 7800

MenABCW-##Y ## OVERVIEW ## Drug Overview ## Product Profiles ## MenABCW-##Y : Meningococcal vaccines LIST OF TABLES ## Table ##: MenABCW-##Y drug profile ## Table ##: Late-phase trials of MenABCW-##Y for meningococcal vaccination ## Table ##: MenABCW-##Y for

  • Meningococcal
  • Vaccine
  • European Union
  • United States
  • Product Initiative
  • Clinical Trial profile. 151 Trial Title
  • Clinical Trial profile. 251 Trial Title

The prominent features of this report are - ##.

  • Clinical Trial
  • Meningococcal
  • Therapy
  • World
  • Sanofi S.A.
  • SYMPTOMS OF MENINGOCOCCAL DISEASE
  • 5.1 MENINGOCOCCAL IMMUNIZATION POLICY

TABLE ## PROVIDES A SUMMARY OF COMMON MENINGOCOCCAL DISEASE SYMPTOMS.

  • Meningococcal
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

DISEASE OVERVIEW Meningococcal infection is one of the serious and death causing infections worldwide.

  • Meningococcal
  • Pathology
  • World
  • CAUSES OF MENINGOCOCCAL DISEASES
  • Introduction

As of June 2015, over ## million people aged ##-## years received the meningococcal A conjugate vaccination in countries in Africa.

  • Meningococcal
  • Market Size
  • Meningococcal group
  • Pfizer Inc.
  • Sanofi S.A.

## ## ## United Kingdom ## ## ## ## ## France ## ## ## ## ## Germany ## ## ## ## ## Italy ## ## ## ## ## Japan ## ## ## ## ## Canada Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials

  • Infectious Disease
  • Meningococcal
  • World
  • Product Initiative
  • Pfizer Inc.
  • KEY MARKETED VACCINES FOR MENINGOCOCCAL DISEASE
  • Key marketed vaccines for meningococcal disease

Both lots were well tolerated and had similar adverse event profiles Trial Table ##: Bexsero pivotal trial data in meningococcal vaccination Sample size Target Dosing tested and duration patient s Results Reference Follow-up: Two weeks, and one month NCT## (Phase III) ##, ## H

  • Meningococcal
  • United States
  • GlaxoSmithKline plc
  • Meningococcal group
  • Pfizer Inc.
  • APR 24, 2018: HIBERGENE DIAGNOSTICS LAUNCHES NEW RAPID TEST FOR BACTERIAL MENINGITIS
  • VENTURE FINANCING

GlobalData HiberGene Diagnostics Ltd, reported one medical equipment deal each in 2016 and 2017.

  • Diagnostics
  • Meningococcal
  • Ireland
  • Deals & Alliance
  • Hibergene Diagnostics Limited
  • BACTERIAL (PYOGENIC) MENINGITIS THERAPEUTICS CLINICAL TRIALS, GLOBAL, ONGOING CLINICAL TRIALS BY PROMINENT DRUGS, 2017*
  • Clinical Trial profile. 34

## ## ## United Kingdom ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## France ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## Japan Source: GlobalData' s Pharma Intelligence Center Clinical Trials Datab

  • Infectious Disease
  • Meningococcal
  • World
  • Product Initiative
  • Pfizer Inc.
  • Pneumococcal Meningitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

## ## ## ## United Kingdom ## ## ## ## ## France ## ## ## ## ## Germany ## ## ## ## ## Italy ## ## ## ## ## Japan ## ## ## ## ## Canada ## ## ## ## ## Source: GlobalData' s Pharma eTrack Clinical Trials D

  • Infectious Disease
  • Meningococcal
  • Vaccine
  • World
  • Product Initiative

The focus of GSK Vaccines pipeline is to maintain GSK s meningococcal meningitis market leadership with both licensed and candidate vaccines.

  • Meningococcal
  • Neurological Disorder
  • Neurology
  • Patient Monitoring
  • AorTech International plc
  • MENINGOCOCCAL [SEROTYPE B] VACCINE
  • INVASIVE MENINGOCOCCAL DISEASE DUE TO NEISSERIA MENINGITIDIS SEROGROUP B IN PERSONS 10 - 25 YEARS OF AGE.

One month after three doses of bivalent rLP2086, hSBA titers greater than ##:## to diverse meningococcal serogroup B strains were observed in ## to ## percent of subjects and ## to## percent after two doses.

  • Meningococcal
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.